<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYLÂ - erythromycin ethylsuccinate and sulfisoxazole acetylÂ granule, for suspensionÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL FOR ORAL SUSPENSION, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1807275c-d9c7-45f7-a8a3-0fea20cac0dc"></a><a name="section-1"></a><p></p>
<p class="First">Revised MARCH 2007<br>11001190<br></p>
<p>Rx only<br></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_aca3fd0c-a330-4ecf-bdf5-1e3aecb71932"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Erythromycin ethylsuccinate and sulfisoxazole acetyl, when reconstituted with water as directed on the label, the granules form a white, cherry flavored suspension that provides the equivalent of 200 mg erythromycin activity and the equivalent of 600 mg of sulfisoxazole activity per teaspoonful (5 mL).</p>
<p>Erythromycin is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccaropolyspora erythraea</span> and belongs to the macrolide group of antibiotics. It is basic and readily forms salts and esters. Erythromycin ethylsuccinate is the 2â€™-ethylsuccinyl ester of erythromycin. It is essentially a tasteless form of the antibiotic suitable for oral administration, particularly in suspension dosage forms. The chemical name is erythromycin 2â€™-(ethylsuccinate). Erythromycin ethylsuccinate has the following structural formula:</p>
<div class="Figure">
<img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7&amp;name=5a80591d-0c10-4340-844e-ad39079c5048-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">45</span>H<span class="Sub">75</span>NO<span class="Sub">16</span> Molecular Weight: 862.06</p>
</div>
<p>Sulfisoxazole acetyl or <span class="Italics">N<span class="Sup">1</span></span>-acetyl sulfisoxazole is an ester of sulfisoxazole. Chemically, sulfisoxazole is <span class="Italics">N<span class="Sup">1</span></span>-(3,4-dimethyl-5-isoxazotyl) sulfanilamide. Sulfisoxazole acetyl has the following structural formula:</p>
<div class="Figure">
<img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7&amp;name=5a80591d-0c10-4340-844e-ad39079c5048-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">13</span>H<span class="Sub">15</span>N<span class="Sub">3</span>O<span class="Sub">4</span>S Molecular Weight: 309.34 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a48ee21-93cb-4f8b-9d1a-f4e46f385df6"></a><a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients: </h2>
<p class="First">Artificial flavor, lactose anhydrous, methylparaben, polysorbate 80, povidone, simethicone, sodium citrate anhydrous and sucrose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_420a6ee8-507f-4e42-a880-de92e1e94f22"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Orally administered erythromycin ethylsuccinate suspensions are readily and reliably absorbed. Erythromycin ethylsuccinate products have demonstrated rapid and consistent absorption in both fasting and nonfasting conditions. However, higher serum concentrations are obtained when these products are given with food. Erythromycin is largely bound to plasma proteins. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. Erythromycin crosses the placental barrier and is excreted in human milk. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
<p>In the presence of normal hepatic function, erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral administration, less than 5% of the administered dose can be recovered in the active form in the urine.</p>
<p>Wide variation in blood levels may result following identical doses of a sulfonamide. Blood levels should be measured in patients receiving these drugs for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Free sulfonamide blood levels of 50 to 150 mcg/mL may be considered therapeutically effective for most <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, with blood levels of 120 to 150 mcg/mL being optimal for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The maximum sulfonamide level should be 200 mcg/mL, because adverse reactions occur more frequently above this concentration.</p>
<p>Following oral administration, sulfisoxazole is rapidly and completely absorbed; the small intestine is the major site of absorption, but some of the drug is absorbed from the stomach. Sulfonamides are present in the blood as free, conjugated (acetylated and possibly other forms), and protein-bound forms. The amount present as â€œfreeâ€? drug is considered to be the therapeutically active form. Approximately 85% of a dose of sulfisoxazole is bound to plasma proteins, primarily to albumin; 65% to 72% of the unbound portion is in the nonacetylated form.</p>
<p>Maximum plasma concentrations of intact sulfisoxazole following a single 2 g oral dose of sulfisoxazole to healthy adult volunteers ranged from 127 to 211 mcg/mL (mean 169 mcg/mL), and the time of peak plasma concentration ranged from 1 to 4 hours (mean, 2.5 hours). The elimination half-life of sulfisoxazole ranged from 4.6 to 7.8 hours after oral administration. The elimination of sulfisoxazole has been shown to be slower in elderly subjects (63 to 75 years) with diminished renal function (creatine clearance 37 to 68 mL/min).<span class="Sup">1</span> After multiple-dose oral administration of 500 mg q.i.d. to healthy volunteers, the average steady-state plasma concentrations of intact sulfisoxazole ranged from 49.9 to 88.8 mcg/mL (mean 63.4 mcg/mL).<span class="Sup">2</span></p>
<p>Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration. Concentrations of sulfisoxazole are considerably higher in the urine than in the blood. The mean urinary recovery following oral administration of sulfisoxazole is 97% within 48 hours; 52% of this is intact drug, and the remainder is the N<span class="Sup">4</span>-acetylated metabolite.</p>
<p>Sulfisoxazole is distributed only in extracellular body fluids. It is excreted in human milk. It readily crosses the placental barrier. In healthy subjects, cerebrospinal fluid concentrations of sulfisoxazole vary; in patients with <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, however, concentrations of free drug in cerebrospinal fluid as high as 94 mcg/mL have been reported.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89b956a6-80ac-4870-9295-656295744f52"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology:</h2>
<p class="First">This product has been formulated to contain sulfisoxazole for concomitant use with erythromycin.</p>
<p>Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal sub-units of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated <span class="Italics">in vitro</span> between erythromycin and clindamycin, lincomycin, and chloramphenicol.</p>
<p>The sulfonamides are bacteriostatic agents, and the spectrum of activity is similar for all. Sulfonamides inhibit bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with <span class="Italics">para</span>-aminobenzoic acid through competitive inhibition of the enzyme dihydropteroate synthetase. Resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> have altered dihydropteroate synthetase with reduced affinity for sulfonamides or produce increased quantities of <span class="Italics">para</span>-aminobenzoic acid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7aa10582-1243-40b3-8191-65d14078e2a7"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Testing:</h2>
<p class="First">Quantitative methods that require measurement of zone diameter give the most precise estimates of the susceptibility of bacteria to antimicrobial agents. One such standardized single-disc procedure<span class="Sup">3</span> has been recommended for use with discs to test susceptibility to erythromycin and sulfisoxazole. Interpretation involves correlation of the zone diameters obtained in the disc test with minimal inhibitory concentration (MIC) values for erythromycin and sulfisoxazole.</p>
<p>If the standardized procedure of disc susceptibility is used, a 15 mcg erythromycin disc should give a zone diameter of at least 18 mm when tested against an erythromycin-susceptible bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, and a 250-300 mcg sulfisoxazole disc should give a zone diameter of at least 17 mm when tested against a sulfisoxazole-susceptible bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.</p>
<p><span class="Italics">In vitro</span> sulfonamides susceptibility tests are not always reliable because media containing excessive amounts of thymidine are capable of reversing the inhibitory effect of sulfonamides, which may result in false resistant reports. The tests must be carefully coordinated with bacteriological and clinical responses. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the isolation media but not to subsequent susceptibility test media.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_20d18534-eabc-4916-8f7a-af49c7ca4fea"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">For treatment of ACUTE <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span> in children that is caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_22650e87-7ab6-417c-acef-ea0fa44acba4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations:</p>
<dl>
<dt>Â </dt>
<dd>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to either of its components, children younger than 2 months, pregnant women at <span class="Italics">term</span>, and mothers nursing infants less than 2 months of age.</dd>
</dl>
<p>Use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span> in the newborn by displacing bilirubin from plasma proteins.</p>
<p>Erythromycin is contraindicated in patients taking terfenadine. (See PRECAUTIONS, <a href="#i4i_interactions_id_a2b04dc8-7917-4769-893f-d55565e7a0fd">Drug Interactions:</a>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span>, AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span>.</p>
<p>SULFONAMIDES, INCLUDING SULFONAMIDE-CONTAINING PRODUCTS SUCH AS ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL FOR ORAL SUSPENSION, SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASH</span> OR ANY SIGN OF ADVERSE REACTION. In rare instances, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be followed by a more severe reaction, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span>. (See <a href="#i4i_precautions_id_4797e3a2-b805-420c-8b8e-b49530a69f63">PRECAUTIONS</a>.)</p>
<p>Clinical signs such as <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may be early indications of serious reactions.</p>
<p>There have been reports of hepatic dysfunction, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurring in patients receiving oral erythromycin products.</p>
<p><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and pulmonary infiltrates are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> of the respiratory tract that have been reported in association with sulfonamide treatment.</p>
<p>The sulfonamides should not be used for the treatment of group A beta-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>. In an established <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is one primary cause of â€œantibiotic-associated colitisâ€?.</p>
<p>After diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent <span class="product-label-link" type="condition" conceptid="434279" conceptname="Congenital syphilis">congenital syphilis</span>. Infants born to women treated during pregnancy with erythromycin for early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should be treated with an appropriate penicillin regimen.</p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. (See package insert for lovastatin.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_4797e3a2-b805-420c-8b8e-b49530a69f63"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_11cd1f99-15b9-4103-9ea9-4e2dc2742439"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">Erythromycin is principally excreted by the liver. Caution should be exercised when erythromycin is administered to patients with impaired hepatic function. (See <a href="#i4i_clinical_pharmacology_id_420a6ee8-507f-4e42-a880-de92e1e94f22">CLINICAL PHARMACOLOGY</a> and <a href="#i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3">WARNINGS</a> sections.)</p>
<p>Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, erythromycin should be discontinued and appropriate therapy instituted.</p>
<p>There have been reports that erythromycin may aggravate the <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>Sulfonamides should be given with caution to patients with impaired renal or hepatic function and to those with severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. In glucose-6-phosphate dehydrogenase-deficient individuals, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur; this reaction is frequently dose-related.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c8fd4ebf-ec5d-4ea1-8ea2-6a7ed4a9d9c2"></a><a name="section-7.2"></a><p></p>
<h2>Information For Patients:</h2>
<p class="First">Patients should maintain an adequate fluid intake to prevent <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and stone formation.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_5f43ee2a-3ed6-4820-b4ff-8cb2b8eeee5d"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests:</h2>
<p class="First">Complete blood counts should be done frequently in patients receiving sulfonamides. If a significant reduction in the count of any formed blood element is noted, erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension should be discontinued. Urinalysis with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Blood levels should be measured in patients receiving a sulfonamide for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (See <a href="#i4i_indications_id_20d18534-eabc-4916-8f7a-af49c7ca4fea">INDICATIONS AND USAGE</a>.)</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_2a1244a3-611b-4b3b-a55f-a119d4111ce1"></a><a name="section-7.4"></a><p></p>
<h2>Drug Laboratory Test Interactions:</h2>
<p class="First">Erythromycin interferes with the fluorometric determination of urinary catecholamines.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a2b04dc8-7917-4769-893f-d55565e7a0fd"></a><a name="section-7.5"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.</p>
<p>Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.</p>
<p>There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to this drug may be more pronounced in the elderly.</p>
<p>Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>.</p>
<p>Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.</p>
<p>The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs. There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, hexobarbital, phenytoin, allentanil, diisopyramide, lovastatin, and bromocriptine. Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.</p>
<p>Erythromycin significantly alters the metabolism of terfenadine when taken concomitantly. Rare cases of serious cardiovascular adverse events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, have been observed. (See <a href="#i4i_contraindications_id_22650e87-7ab6-417c-acef-ea0fa44acba4">CONTRAINDICATIONS</a>.)</p>
<p>It has been reported that sulfisoxazole may prolong the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.</p>
<p>It has been proposed that sulfisoxazole competes with thiopental for plasma protein binding. In one study involving 48 patients, intravenous sulfisoxazole resulted in a decrease in the amount of thiopental required for anesthesia and in a shortening of the awakening time. It is not known whether chronic oral doses of sulfisoxazole have a similar effect. Until more is known about this interaction, physicians should be aware that patients receiving sulfisoxazole might require less thiopental for anesthesia.</p>
<p>Sulfonamides can displace methotrexate from plasma protein binding sites, thus increasing free methotrexate concentrations. Studies in man have shown sulfisoxazole infusions to decrease plasma protein-bound methotrexate by one fourth.</p>
<p>Sulfisoxazole can also potentiate the blood-sugar-lowering activity of sulfonylureas.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d02b6e0f-ecc7-4e23-bad1-a113622f4dee"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94c91d8f-acdc-4bb9-a75a-30ca5d659d19"></a><a name="section-7.6.1"></a><p></p>
<h3>
<span class="Bold">Carcinogenesis</span>:</h3>
<p class="First">Erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension has not undergone adequate trials relating to carcinogenicity: each component, however, has been evaluated separately. Long-term (21 month) oral studies conducted in rats with erythromycin ethylsuccinate did not provide evidence of tumorigenicity. Sulfisoxazole was not carcinogenic in either sex when administered to mice by gavage for 103 weeks at dosages up to approximately 18 times the recommended human dose or to rats at 4 times the human dose. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term administration of sulfonamides has resulted in thyroid malignancies in this species.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_db7fe730-1db9-4369-acaf-d782272e78cc"></a><a name="section-7.6.2"></a><p></p>
<h3><span class="Bold">Mutagenesis:</span></h3>
<p class="First">There are no studies available that adequately evaluate the mutagenic potential of erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension or either of its components. However, sulfisoxazole was not observed to be mutagenic in <span class="Italics">E. coli</span> Sd-4-73 when tested in the absence of a metabolic activating system. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82b79f76-b5a1-4b93-bfe6-01c15357944a"></a><a name="section-7.6.3"></a><p></p>
<h3><span class="Bold">Impairment of Fertility:</span></h3>
<p class="First">Erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension has not undergone adequate trials relating to impairment of fertility. In a reproduction study in rats given 7 times the human dose per day of sulfisoxazole, no effects were observed regarding mating behavior, conception rate or fertility index (percent pregnant).</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d57b63c8-7f4b-4fb8-81fd-4ecbf87eb56f"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_6f8a685a-4d08-4e0e-b37b-7c50fd8a7d51"></a><a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1198ba41-bee4-4911-a7d8-0a76024f67b0"></a><a name="section-7.7.1.1"></a><p></p>
<h4>Pregnancy Category C: </h4>
<p class="First">At dosages 7 times the human daily dose, sulfisoxazole was not teratogenic in either rats or rabbits. However, in two other <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> developed in both rats and mice after administration of 5 to 9 times the human therapeutic dose of sulfisoxazole.</p>
<p>There is no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effects on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation, and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.</p>
<p>There are no adequate or well-controlled studies of erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension in either laboratory animals or in pregnant women. It is not known whether erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension can cause fetal harm when administered to a pregnant woman prior to term or can affect reproduction capacity. Erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_934304d1-28fc-4d10-94cc-9781d568c842"></a><a name="section-7.7.2"></a><p></p>
<h3>Nonteratogenic Effects:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">Kernicterus</span> may occur in the newborn as a result of treatment of a pregnant woman <span class="Italics">at term</span> with sulfonamides. (See <a href="#i4i_contraindications_id_22650e87-7ab6-417c-acef-ea0fa44acba4">CONTRAINDICATIONS:</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_6d25c2d2-cc67-4b5d-b392-711981c8e390"></a><a name="section-7.8"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">The effects of erythromycin and sulfisoxazole on labor and delivery are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_abd5f357-03a9-4a07-bb13-f24cc4157534"></a><a name="section-7.9"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Both erythromycin and sulfisoxazole are excreted in human milk. <span class="Bold">Because of the potential for the development of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span> in neonates due to the displacement of bilirubin from plasma proteins by sulfisoxazole, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. (</span>See <a href="#i4i_contraindications_id_22650e87-7ab6-417c-acef-ea0fa44acba4">CONTRAINDICATIONS:</a></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1c0b393c-00b8-4301-97ad-85fc8a97d59f"></a><a name="section-7.10"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">See<a href="#i4i_indications_id_20d18534-eabc-4916-8f7a-af49c7ca4fea"> INDICATIONS AND USAGE</a> and <a href="#i4i_dosage_admin_id_70c590f9-c954-4d8b-9408-f8e01eac6ad8">DOSAGE AND ADMINISTRATION </a>sections. Not for use in children under 2 months of age. (See <a href="#i4i_contraindications_id_22650e87-7ab6-417c-acef-ea0fa44acba4">CONTRAINDICATIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_8cd438f6-e074-42bd-89ce-a61d881654db"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79f75b98-e442-4155-9683-e3e1df300d78"></a><a name="section-8.1"></a><p></p>
<h2>Erythromycin Ethylsuccinate:</h2>
<p class="First">The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Symptoms of hepatic dysfunction and/or abnormal liver-function test results may occur (see <a href="#i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3">WARNINGS</a> section). <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been rarely reported in association with erythromycin therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred.</p>
<p>There have been isolated reports of reversible <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> occurring chiefly in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients receiving high doses of erythromycin.</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during of after antibiotic treatment. (See <a href="#i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91fcefc0-b0b1-43b0-8f1d-8e4db29daf3f"></a><a name="section-8.2"></a><p></p>
<h2>Sulfisoxazole Acetyl:</h2>
<p class="First">Included in the listing that follows are adverse reactions that have been reported with other sulfonamide products: pharmacologic similarities require that each of the reactions be considered with erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6f88679-1858-4edb-bff9-5c98dee57be6"></a><a name="section-8.2.1"></a><p></p>
<h3>Allergic/Dermatologic: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (Lyellâ€™s syndrome), <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, allergic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, and conjunctival and scleral injection. In addition, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> have been reported. (See <a href="#i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b2c1f46-08a3-495d-a21a-0282a96acece"></a><a name="section-8.2.2"></a><p></p>
<h3>Cardiovascular: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>.</p>
<p>Rarely, erythromycin has been associated with the production of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, in individuals with prolonged QT intervals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9816e78f-d305-4bc9-bc17-84e896eee4bc"></a><a name="section-8.2.3"></a><p></p>
<h3>Endocrine: </h3>
<p class="First">The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. Developments of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> has occurred rarely in patients receiving sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0ef12c1-d96d-4a98-8f8a-373921c2bd0a"></a><a name="section-8.2.4"></a><p></p>
<h3>Gastrointestinal: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, hepatocellular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="28461" conceptname="Hypertrophy of salivary gland">salivary gland enlargement</span>, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after treatment with sulfisoxazole, a component of erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension. (See <a href="#i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3">WARNINGS</a>.)</p>
<dl>
<dt>Â </dt>
<dd>The sulfisoxazole acetyl component of erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension has been reported to cause increased elevation of liver-associated enzymes in patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb51621c-2146-4ffa-a8c6-55771344d421"></a><a name="section-8.2.5"></a><p></p>
<h3>Genitourinary: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, BUN and creatinine elevations, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, and toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span> with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have also been reported.</p>
<dl>
<dt>Â </dt>
<dd>The frequency of renal complications, commonly associated with some sulfonamides, is lower in some patients receiving the more soluble sulfonamides such as sulfisoxazole.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c05241e0-82cb-4da0-b5d7-2525c7475e8d"></a><a name="section-8.2.6"></a><p></p>
<h3>Hematologic: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span> including hypopro-thrombinemia and <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span>, <span class="product-label-link" type="condition" conceptid="4137763" conceptname="Sulfhemoglobinemia">sulfhemoglobinemia</span>, and <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c43512fc-2799-42ba-ac3d-85ebf38b1956"></a><a name="section-8.2.7"></a><p></p>
<h3>Neurologic: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a63c865-d769-4141-86ad-18086b23bf85"></a><a name="section-8.2.8"></a><p></p>
<h3>Psychiatric: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1bb625f-8590-4416-b1a2-454029f010d1"></a><a name="section-8.2.9"></a><p></p>
<h3>Respiratory: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and pulmonary infiltrates. (See <a href="#i4i_warnings_id_4ac09f2c-4e44-4db9-93db-da20926751b3">WARNINGS</a>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_08ecc6b9-e5bd-4d90-97aa-7eb7e4a0904c"></a><a name="section-8.2.10"></a><p></p>
<h3>Vascular: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b031117-7aa8-4225-81fa-6bde5f6a2b40"></a><a name="section-8.2.11"></a><p></p>
<h3>Miscellaneous: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, (including periorbital), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_44fa8f4f-d17f-4b56-910b-3e0a130570cd"></a><a name="section-9"></a><p></p>
<h1>Overdosage:</h1>
<p class="First">No information is available on a specific result of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension. Overdosage of erythromycin should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
<p>The amount of a single dose of sulfisoxazole that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> may be noted. <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> are potential late manifestations of overdosage.</p>
<p>General principles of treatment include the immediate discontinuation of the drug, instituting gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, forcing oral fluids, and administering intravenous fluids if urine output is low and renal function is normal. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If the patient becomes cyanotic, the possibility of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> should be considered and, if present, the condition should be treated appropriately with intravenous 1% methylene blue. If a significant <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective, and hemodialysis is only moderately effective in removing sulfonamides.</p>
<p>The acute toxicity of sulfisoxazole in animals is as follows:</p>
<a name="id_bee0b448-cfc0-4f29-bd6b-22d47286f2d5"></a><table border="none" width="275.000">
<col width="36.0%">
<col width="64.0%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top">
<br><span class="Underline">Species</span>
</td>
<td align="center" valign="top">
<p class="First">LD<span class="Sub">50</span>=S.E. </p>
<span class="Underline">(mg/kg)</span>
</td>
</tr>
<tr>
<td align="left" valign="top">mouse</td>
<td align="center" valign="top">5700 = 235</td>
</tr>
<tr>
<td align="left" valign="top">rats</td>
<td align="center" valign="top">Â± 10,000</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">rabbits</td>
<td class="Botrule" align="center" valign="top">Â± 2000</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_70c590f9-c954-4d8b-9408-f8e01eac6ad8"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL FOR ORAL SUSPENSION SHOULD NOT BE ADMINISTERED TO INFANTS UNDER 2 MONTHS OF AGE BECAUSE OF CONTRAINDICATIONS OF SYSTEMIC SULFONAMIDES IN THIS AGE GROUP.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2630e182-5ad1-44ed-8869-c135ed5525fa"></a><a name="section-10.1"></a><p></p>
<h2>For Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> in Children: </h2>
<p class="First">The dose of erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension can be calculated based on the erythromycin component (50 mg/kg/day) or the sulfisoxazole component (150 mg/kg/day to a maximum of 6 g/day). The total daily dose of erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension should be administered in equally divided doses three or four times a day for 10 days. Erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension may be administered without regard to meals.</p>
<p>The following approximate dosage schedules are recommended for using erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f62df87-a125-46bd-89c0-bfe610ffe477"></a><a name="section-10.2"></a><p></p>
<h2>Children: </h2>
<p class="First">Two months of age or older</p>
<a name="id_3cc33315-b882-4a62-81a3-90fe6c4e3555"></a><table border="single" width="461.000">
<col width="56.0%">
<col width="44.0%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="left" colspan="2" valign="top">FOUR-TIMES-A-DAY SCHEDULE</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Weight</td>
<td class="Botrule" align="left" valign="top">Dose - every 6 hours</td>
</tr>
<tr>
<td align="left" valign="top">Less than 8 kg (&lt;18 lbs)</td>
<td align="left" valign="top">Adjust dosage by body weight</td>
</tr>
<tr>
<td align="left" valign="top">8 kg (18 lbs)</td>
<td align="left" valign="top">1/2 teaspoonful (2.5 mL)</td>
</tr>
<tr>
<td align="left" valign="top">16 kg (35 lbs)</td>
<td align="left" valign="top">1 teaspoonful (5 mL)</td>
</tr>
<tr>
<td align="left" valign="top">24 kg (53 lbs)</td>
<td align="left" valign="top">1-1/2 teaspoonfuls (7.5 mL)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Over 32 kg (over 70 lbs)</td>
<td class="Botrule" align="left" valign="top">2 teaspoonfuls (10 mL)</td>
</tr>
<tr><td class="Botrule" align="left" colspan="2" valign="top">THREE-TIMES-A-DAY SCHEDULE</td></tr>
<tr>
<td class="Botrule" align="left" valign="top">Weight</td>
<td class="Botrule" align="left" valign="top">Dose - every 8 hours</td>
</tr>
<tr>
<td align="left" valign="top">Less than 6 kg (&gt;13 lbs)</td>
<td align="left" valign="top">Adjust dosage by body weight</td>
</tr>
<tr>
<td align="left" valign="top">6 kg (13 lbs)</td>
<td align="left" valign="top">1/2 teaspoonful (2.5 mL)</td>
</tr>
<tr>
<td align="left" valign="top">12 kg (26 lbs)</td>
<td align="left" valign="top">1 teaspoonful (5 mL)</td>
</tr>
<tr>
<td align="left" valign="top">18 kg (40 lbs)</td>
<td align="left" valign="top">1-1/2 teaspoonfuls (7.5 mL)</td>
</tr>
<tr>
<td align="left" valign="top">24 kg (53 lbs)</td>
<td align="left" valign="top">2 teaspoonfuls (10 mL)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Over 30 kg (over 66 lbs)</td>
<td class="Botrule" align="left" valign="top">2-1/2 teaspoonfuls (12.5 mL)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_fea0207d-0843-40e6-8436-97b65c2aae6a"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Erythromycin Ethylsuccinate and Sulfisoxazole Acetyl for Oral Suspension is available for teaspoon dosage in 100 mL <span class="Bold">(NDC 54868-0971-1)</span> bottles, in the form of granules to be reconstituted with water. <br></p>
<p>The suspension provides erythromycin ethylsuccinate equivalent to 200 mg erythromycin activity and sulfisoxazole acetyl equivalent to 600 mg sulfisoxazole per teaspoonful (5 mL).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_2a71f4c1-8a4e-4df8-a54d-f97a9a624845"></a><a name="section-11.1"></a><p></p>
<p class="First">Store at room temperature in dry form.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_c9c04bcd-65ed-44dd-a5ea-2bac1c4a612b"></a><a name="section-12"></a><p></p>
<h1>REFERENCES:</h1>
<ol>
<li>Biovert A, Barbeau G. Belanger PM: Pharmacokinetics of sulfisoxazole in young and elderly subjects. <span class="Italics">Gerontology</span> 1984; 30: 125-131.</li>
<li>Oie S. Gambertoglio JG, Fleckenstein L: Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. <span class="Italics">J Pharmacokinet Biopharm</span> 1982; 10: 157 - 172.</li>
<li>National Committee for Clinical Laboratory Standards: <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests</span>, ed 4. Approved Standard NCCLS Document M2-A4, Vol 10, No. 7. Villanova, Pa: NCCLS, 1990.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b66b4084-094b-4b42-b91a-f1f4571879ab"></a><a name="section-13"></a><p></p>
<p class="First">Manufactured by <span class="Bold">Duramed Pharmaceuticals, Inc.</span><br>Packaged by Pharmaceutics International, Inc.<br>Hunt Valley, Maryland 21031<br></p>
<p>for <span class="Bold">Duramed Pharmaceuticals, Inc.<br>Subsidiary of Barr Pharmaceuticals, Inc.<br>Pomona, NY 10970</span></p>
<p>Revised MARCH 2007<br>BR-0445</p>
<br><p><br></p>
<p>Relabeling of "Additional Barcode" label by:<br>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â  74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_63673eee-874a-498e-989b-f8c8b1dd2718"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Image of 100 mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7&amp;name=package%20label.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77fa3a37-6162-476a-b683-49fc970334b8"></a><a name="section-14.1"></a><p></p>
<h2>100 mL Label Text</h2>
<p class="First"><span class="Bold">E.S.P.</span> (R)</p>
<p><span class="Bold">Erythromycin Ethylsuccinate</span></p>
<p><span class="Bold">and Sulfisoxazole Acetyl</span></p>
<p><span class="Bold">for Oral Suspension, USP</span></p>
<p><span class="Bold">200 mg</span> erythromycin activity</p>
<p>and the equivalent of</p>
<p><span class="Bold">600 mg</span> sulfisoxazole</p>
<p>per 5 mL reconstituted</p>
<p><span class="Bold">100 mL</span> (when mixed) <span class="Bold"><br></span></p>
<p><span class="Bold">Rx only</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYLÂ 		
					</strong><br><span class="contentTableReg">erythromycin ethylsuccinate and sulfisoxazole acetyl granule, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0971(NDC:51285-445-22)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN ETHYLSUCCINATE</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN ETHYLSUCCINATE</td>
<td class="formItem">200Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SULFISOXAZOLE ACETYL</strong> (SULFISOXAZOLE) </td>
<td class="formItem">SULFISOXAZOLE ACETYL</td>
<td class="formItem">600Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS TRISODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0971-1</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062759</td>
<td class="formItem">10/11/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>da5a96d1-9f4b-439b-890e-a39bc29bdf5e</div>
<div>Set id: eb6ea746-3228-4969-8a26-653288662fd7</div>
<div>Version: 1</div>
<div>Effective Time: 20091120</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
